secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000427
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome increases Hercules loan to $350M, cuts rate, extends maturity to 2028/2029
--------------------------------------------------------------------------------

- Total loan commitment raised to $350M from $300M; interest rate is greater of 9.95% or prime+2.20%.
- Maturity extended to Jan 1, 2028 (or Jan 1, 2029 if revenue targets met); minimum cash covenant $30M.
- Company believes current cash plus remaining committed capital sufficient to fund operations to cash flow positivity.
- Amended tranche structure with $95M, $55M, $30M, $35M, $35M sub-tranches for Tranche 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023000427/0000950170-23-000427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023000427/axsm-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer